Structural Heart Devices Global Market - Forecast to 2027

Publishing Date : July, 2020
Report Code : HCMD0133
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Structural heart devices consist of the various therapeutic interventional devices used to efficiently and economically close an abnormal communication between the heart chambers or to reconstruct or replace a diseased or degenerated heart valve through the adoption of a multidisciplinary remedial approach. Compared to the traditional highly invasive open heart surgical repair and replacement procedures, the current minimally invasive transcatheter therapeutic procedures with highly efficient, technologically advanced products assure patients and healthcare providers with improved efficiency, effectiveness and quicker restoration of the non coronary physical defects of the heart. Increased utilization of the various structural heart therapeutic products for the numerous and varied types of structural heart diseases among the patients, elevating inclination of the value centric global patient pool towards the minimally invasive, technologically advanced structural heart products with better therapeutic outcomes and the need to reduce hospitalization duration and ease and improve the patient’s condition quickly through durable structural heart interventional products are fuelling the structural heart devices global market.

As estimated by IQ4I Research, the structural heart devices global market is expected to reach $17,433.4 million by 2027 growing at a double digit CAGR from 2020 to 2027, due to elevating prevalence of various kinds of structural heart diseases, increasing expanded indication approval for various transcatheter structural heart products, persistently increasing geriatric population burdened with various kinds of degenerative valvular hear diseases, increasing demand for highly efficient, minimally invasive structural heart therapeutic products from the value centric patient population, increasing R&D spending for developing innovative and technologically advanced products, growing economies and increasing demand for better healthcare facilities in emerging markets. The structural heart devices market is segmented by product (product type), indication and geography.

Based on the product, the structural heart devices global market is segmented into structural heart repair and structural heart replacement devices. Among these products, structural heart replacement segment is the largest product segment in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027. Structural heart repair devices segment is the fastest emerging segment growing at a low teen CAGR from 2020 to 2027. Among the various structural heart repair products like Annuloplasty repair devices, valvuloplasty devices, occluders, Transcatheter mitral valve repair devices and other repair devices like chordal implants, transcatheter mitral valve repair product segment accounted for the largest revenue in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027. Other structural heart repair device segment is the fastest emerging segment and is expected to exhibit exponential growth during the forecasted period. Among the structural heart replacement devices, Transcatheter valve replacement device segment accounted for the largest revenue in 2020 and is expected to grow at mid teen CAGR from 2020 to 2027. In the surgical valve replacement device global market by product type, tissue valve segment accounted for the largest revenue of in 2020. Among the Transcatheter valve replacement devices, Transcatheter aortic valve replacement (TAVR) device segment holds the largest share in 2020 and is expected to grow at low teen CAGR from 2020 to 2027 while Transcatheter mitral valve replacement (TMVR) product segment is the fastest emerging segment and is expected to show an exponential growth during the forecasted period.

Based on the indication, the structural heart devices global market is segmented into heart valve diseases, congenital heart diseases and other structural heart diseases. Among these, the heart valve disease segment commanded the largest revenue in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Among the various heart valve diseases, aortic valve disease segment holds the largest share in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027 while mitral valve disease segment is the fastest emerging segment and is expected to show mid teen CAGR during the forecasted period.

Based on the region, the structural heart devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Turkey, Rest of Latin America and Middle East & Africa). North America accounted for the largest revenue in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027 due to increasing prevalence of structural heart diseases, escalating geriatric population burdened with degenerative valvular heart diseases, increasing demand for highly efficient, durable, minimally invasive and technologically advanced structural heart therapeutic products from the value centric patient population, increasing R&D spending for developing innovative and technologically advanced products, substantial insurance coverage for the interventional procedures there.

The Asia-Pacific is the fastest growing region in structural heart devices market in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027 due to elevating structural heart disease burden in the region, escalating geriatric population, increasing demand for better healthcare facilities, increasing penetration of reimbursement schemes in developing countries, elevating demand for highly efficient and minimally invasive products from the value centric patient population, growing economies of the region, availability of various kinds of structural heart therapeutic products, increasing patient awareness of these products and increasing medical tourism prospects of the region.

The structural heart devices global market is consolidated with few companies dominating the market that offers fewer opportunities for entry for small and medium-sized companies with distinct products in the market. The top players in structural heart devices market are Edwards Lifesciences Corporation (U.S.), Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Livanova PLC (U.K.), Boston Scientific Corporation (U.S.), Cryolife Inc. (U.S.), AtriCure, Inc. (U.S.), Venus Medtech (Hangzhou) Inc (China), Lifetech Scientific Corporation (China), NuMed Inc. (U.S.) and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • Italy
  • France
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Turkey
  • Rest of LATAM & MEA
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING PREVALENCE OF STRUCTURAL HEART DISEASES
        • 3.3.1.2     INCREASING ADOPTION OF MINIMALLY INVASIVE SURGERY FOR STRUCTURAL HEART DISEASES
        • 3.3.1.3     INCREASING EXPANDED INDICATION APPROVAL OF TAVR PRODUCTS
        • 3.3.1.4     VAST STRUCTURAL HEART PRODUCT PIPELINE AND SIGNIFICANT R&D INVESTMENTS
        • 3.3.1.5     EMERGENCE OF TECHNOLOGICALLY ADVANCED PRODUCTS
        • 3.3.1.6     PERSISTENTLY ESCALATING GERIATRIC POPULATION WITH STRUCTURAL HEART DISEASES
        • 3.3.1.7     ACQUISITIONS TO OPEN AN ARRAY OF OPPORTUNITIES FOR THE MARKET TO FLOURISH
        • 3.3.1.8     AVAILABILITY OF ADVANCED IMAGING TECHNIQUES AND INCREASING ACCESS TO NEONATAL SCREENING PROGRAMS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     LACK OF SKILLED AND TRAINED PROFESSIONALS
        • 3.3.2.2     HIGH COST OF THE ADVANCED STRUCTURAL HEART DEVICES
        • 3.3.2.3     ADVERSE EFFECTS OF STRUCTURAL HEART DEVICES
        • 3.3.2.4     UNFAVOURABLE REIMBURSEMENT POLICIES IN DEVELOPING NATIONS
        • 3.3.2.5     STRINGENT REGULATORY BODIES GUIDING STRUCTURAL HEART DEVICE MANUFACTURERS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 14644-1 CLEAN ROOM STANDARDS
        • 3.4.1.3     ISO 13485 MEDICAL DEVICES
        • 3.4.1.4     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
        • 3.4.1.5     ISO 14971: RISK MANAGEMENT OF MEDICAL DEVICES
        • 3.4.1.6     ISO 5840 : HEART VALVE VALIDATION
        • 3.4.1.7     IEC 60601-1 MEDICAL ELECTRICAL EQUIPMENT STANDARD
        • 3.4.1.8     IEC 60601-1-11 HOME CARE SAFETY
      • 3.4.2     ASTM INTERNATIONAL STANDARDS
      • 3.4.3     U.S.
      • 3.4.4     CANADA
      • 3.4.5     EUROPE
      • 3.4.6     JAPAN
      • 3.4.7     CHINA
      • 3.4.8     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
    • 3.6     PATENT TRENDS
    • 3.7     TECHNOLOGICAL ADVANCEMENTS
      • 3.7.1     INTRODUCTION
      • 3.7.2     POLYMERIC HEART VALVES
      • 3.7.3     ULTRASOUND DEVICE FOR AORTIC STENOSIS
      • 3.7.4     BIODEGRADABLE OCCLUDERS
      • 3.7.5     VALVE IN VALVE PROCEDURE
      • 3.7.6     ADJUSTABLE ANNULOPLASTY RINGS
      • 3.7.7     SUTURELESS AORTIC VALVE SYSTEMS
    • 3.8     UPCOMING TECHNOLOGIES
      • 3.8.1     BIOENGINEERED LIVING OR REGENERATIVE HEART VALVES
      • 3.8.2     3-D BIOPRINTED HEART VALVE
    • 3.9     CLINICAL TRIALS
    • 3.10     FUNDING SCENARIO
    • 3.11     STRUCTURAL HEART DEVICES - PRODUCT PIPELINE ANALYSIS
    • 3.12     STRUCTURAL HEART DEVICE REGULATORY APPROVAL ANALYSIS
    • 3.13     PORTER’S FIVE FORCE ANALYSIS
      • 3.13.1     THREAT OF NEW ENTRANTS
      • 3.13.2     THREAT OF SUBSTITUTES
      • 3.13.3     BARGAINING POWER OF SUPPLIERS
      • 3.13.4     BARGAINING POWER OF BUYERS
      • 3.13.5     COMPETITIVE RIVALRY
    • 3.14     SUPPLY CHAIN ANALYSIS
    • 3.15     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.15.1     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.15.2     MARKET SHARE ANALYSIS OF ANNULOPLASTY REPAIR DEVICES BY MAJOR PLAYERS
      • 3.15.3     MARKET SHARE ANALYSIS OF OCCLUDERS BY MAJOR PLAYERS
      • 3.15.4     MARKET SHARE ANALYSIS OF MECHANICAL VALVE REPLACEMENT DEVICES BY MAJOR PLAYERS
      • 3.15.5     MARKET SHARE ANALYSIS OF TISSUE VALVE REPLACEMENT DEVICES BY MAJOR PLAYERS
      • 3.15.6     MARKET SHARE ANALYSIS OF TRANSCATHETER AORTIC VALVE REPLACEMENT BY MAJOR PLAYERS
        • 3.15.6.1     GLOBAL TAVR DEVICES MARKET SHARE ANALYSIS, BY KEY PLAYERS 2020 (%)
        • 3.15.6.2     EUROPE TAVR DEVICES MARKET SHARE ANALYSIS, BY KEY PLAYERS 2020 (%)
        • 3.15.6.3     U.S. TAVR DEVICES MARKET SHARE ANALYSIS, BY KEY PLAYERS 2020 (%)
      • 3.15.7     MARKET SHARE ANALYSIS OF VALVULOPLASTY REPAIR DEVICES BY MAJOR PLAYERS
    • 3.16     STRUCTURAL HEART DEVICES MARKET PENETRATION, PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED
    • 3.17     STRUCTURAL HEART DEVICES NUMBER OF UNITS BY REGION
      • 3.17.1     OCCLUDERS NUMBER OF UNITS BY REGION
      • 3.17.2     TRANSCATHETER MITRAL VALVE REPAIR DEVICES NUMBER OF UNITS BY REGION
      • 3.17.3     SURGICAL VALVE REPAIR - ANNULOPLASTY DEVICES NUMBER OF UNITS BY REGION
      • 3.17.4     TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) DEVICES NUMBER OF UNITS BY REGION
      • 3.17.5     TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) DEVICES NUMBER OF UNITS BY REGION
      • 3.17.6     TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR) DEVICES NUMBER OF UNITS BY REGION
    • 3.18     TAVR CENTERS
    • 3.19     STRUCTURAL HEART DEVICES COMPANY COMPARISON TABLE BY PRODUCTS
      • 3.19.1     TRANSCATHETER HEART VALVE COMPANY COMPARISON TABLE BY PRODUCT AND INDICATION
      • 3.19.2     OCCLUDERS COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
      • 3.19.3     VALVULOPLASTY COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
      • 3.19.4     ANNULOPLASTY COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
      • 3.19.5     MECHANICAL HEART VALVES COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
      • 3.19.6     TISSUE HEART VALVES COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
  • 4     STRUCTURAL HEART DEVICES GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     STRUCTURAL HEART REPAIR DEVICES
      • 4.2.1     ANNULOPLASTY REPAIR DEVICES
      • 4.2.2     VALVULOPLASTY
      • 4.2.3     OCCLUDERS
      • 4.2.4     TRANSCATHETER MITRAL VALVE REPAIR DEVICES
      • 4.2.5     OTHER STRUCTURAL HEART REPAIR DEVICES
    • 4.3     STRUCTURAL HEART VALVE REPLACEMENT DEVICES
      • 4.3.1     INTRODUCTION
      • 4.3.2     SURGICAL VALVE REPLACEMENT DEVICES
        • 4.3.2.1     MECHANICAL HEART VALVES
        • 4.3.2.2     TISSUE HEART VALVES (BIOLOGICAL VALVES)
      • 4.3.3     TRANSCATHETER VALVE REPLACEMENT DEVICES
        • 4.3.3.1     TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
        • 4.3.3.2     TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR)
        • 4.3.3.3     TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR)
  • 5     STRUCTURAL HEART DEVICES GLOBAL MARKET, BY INDICATION
    • 5.1     INTRODUCTION
    • 5.2     HEART VALVE DISEASES
      • 5.2.1     MITRAL VALVE DISEASES
      • 5.2.2     AORTIC VALVE DISEASES
      • 5.2.3     OTHER HEART VALVE DISEASES
    • 5.3     CONGENITAL HEART DISEASES
    • 5.4     OTHER STRUCTURAL HEART DISEASES
  • 6     REGIONAL ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
      • 6.2.1     U.S.
      • 6.2.2     REST OF NORTH AMERICA
    • 6.3     EUROPE
      • 6.3.1     GERMANY
      • 6.3.2     ITALY
      • 6.3.3     FRANCE
      • 6.3.4     REST OF EUROPE
    • 6.4     APAC
      • 6.4.1     JAPAN
      • 6.4.2     CHINA
      • 6.4.3     INDIA
      • 6.4.4     REST OF APAC
    • 6.5     ROW
      • 6.5.1     BRAZIL
      • 6.5.2     TURKEY
      • 6.5.3     REST OF LATAM & MEA
  • 7     COMPETITIVE LANDSCAPE
    • 7.1     INTRODUCTION
    • 7.2     PRODUCT APPROVALS
    • 7.3     ACQUISITIONS
    • 7.4     PRODUCT LAUNCH
    • 7.5     PARTNERSHIPS
    • 7.6     OTHER DEVELOPMENTS
  • 8     MAJOR COMPANIES
    • 8.1     ABBOTT LABORATORIES
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     ATRICURE, INC.
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     BOSTON SCIENTIFIC CORPORATION
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     CRYOLIFE, INC.
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     EDWARDS LIFESCIENCES CORPORATION
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     LIFETECH SCIENTIFIC CORPORATION
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     LIVANOVA PLC
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     MEDTRONIC PUBLIC LIMITED COMPANY
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     NUMED INC.
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     VENUS MEDTECH (HANGZHOU) INC.
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     OCCLUDERS NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 3     TRANSCATHETER MITRAL VALVE REPAIR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 4     ANNULOPLASTY DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 5     TAVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 6     TMVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 7     TPVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 8     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 9     STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 10     STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 11     ANNULOPLASTY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 12     VALVULOPLASTY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 13     OCCLUDERS GLOBAL MARKET REGION, BY REGION, (2019-2027) ($MN)
      • TABLE 14     TRANSCATHETER MITRAL VALVE REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     OTHER STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 16     STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 17     STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 19     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 20     MECHANICAL HEART VALVES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     TISSUE HEART VALVES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 22     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 23     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     TRANSCATHETER AORTIC VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     TRANSCATHETER MITRAL VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     TRANSCATHETER PULMONARY VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 27     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
      • TABLE 28     HEART VALVE DISEASES GLOBAL MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
      • TABLE 29     HEART VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     MITRAL VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019 -2027) ($MN)
      • TABLE 31     AORTIC VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 32     OTHER HEART VALVE DISEASES GLOBAL MARKET REGION, BY REGION, (2019-2027) ($MN)
      • TABLE 33     CONGENITAL HEART DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     OTHER STRUCTURAL HEART DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 37     NORTH AMERICA STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 38     NORTH AMERICA STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 39     NORTH AMERICA SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 40     NORTH AMERICA TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 41     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
      • TABLE 42     NORTH AMERICA HEART VALVE DISEASE MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
      • TABLE 43     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 44     NORTH AMERICA TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 45     EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 46     EUROPE STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 47     EUROPE STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 48     EUROPE SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 49     EUROPE TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 50     EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
      • TABLE 51     EUROPE HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
      • TABLE 52     EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 53     EUROPE TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 54     APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 55     APAC STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 56     APAC STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 57     APAC SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 58     APAC TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 59     APAC STRUCTURAL HEART DISEASE MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
      • TABLE 60     APAC HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
      • TABLE 61     APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 62     APAC TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 63     ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 64     ROW STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 65     ROW STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 66     ROW SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 67     ROW TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 68     ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
      • TABLE 69     ROW HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
      • TABLE 70     ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 71     ROW TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 72     PRODUCT APPROVALS (2018 - 2020)
      • TABLE 73     ACQUISITIONS (2018 - 2020)
      • TABLE 74     PRODUCT LAUNCH (2018 - 2020)
      • TABLE 75     PARTNERSHIPS (2018 - 2020)
      • TABLE 76     OTHER DEVELOPMENTS (2018 - 2020)
      • TABLE 77     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
      • TABLE 78     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 79     ABBOTT LABORATORIES: TOTAL REVENUE, BY MEDICAL DEVICE SEGMENTS (2017-2019) ($MN)
      • TABLE 80     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
      • TABLE 81     ATRICURE INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 82     ATRICURE INC.: TOTAL REVENUE BY PRODUCT SEGMENTS, (2017-2019) ($MN)
      • TABLE 83     ATRICURE INC.: TOTAL REVENUE BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 84     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
      • TABLE 85     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 86     BOSTON SCIENTIFIC CORPORATION: CARDIOVASCULAR REVENUE BY SUB-SEGMENTS, (2017-2019) ($MN)
      • TABLE 87     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 88     CRYOLIFE INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 89     CRYOLIFE INC.: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 90     CRYOLIFE INC.: MEDICAL DEVICES REVENUE BY, SUB-SEGMENTS, (2017-2019) ($MN)
      • TABLE 91     CRYOLIFE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 92     EDWARDS LIFESCIENCES CORP: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 93     EDWARDS LIFESCIENCES CORP: TOTAL REVENUE, BY PRODUCT SEGMENTS, (2017-2019) ($MN)
      • TABLE 94     EDWARDS LIFESCIENCES CORP: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 95     LIFETECH SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
      • TABLE 96     LIFETECH SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
      • TABLE 97     LIFETECH SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 98     LIVANOVA PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 99     LIVANOVA PLC: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 100     LIVANOVA PLC: CARDIOVASCULAR REVENUE, BY SUB-SEGMENTS, (2017-2019) ($MN)
      • TABLE 101     LIVANOVA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 102     MEDTRONIC PLC: TOTAL SALES AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 103     MEDTRONIC PLC: TOTAL SALES, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 104     MEDTRONIC PLC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUB-SEGMENTS, (2017-2019) ($MN)
      • TABLE 105     MEDTRONIC PLC: TOTAL SALES, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 106     VENUS MEDTECH: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 107     VENUS MEDTECH: TOTAL REVENUE, BY PRODUCT SEGMENTS, (2017-2019) ($MN)
      • TABLE 108     VENUS MEDTECH: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)

      LIST OF FIGURES

      • FIGURE 1     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: STRUCTURAL HEART DEVICES GLOBAL MARKET
      • FIGURE 3     STRUCTURAL HEART DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     STRUCTURAL HEART DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     STRUCTURAL HEART DEVICES GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     STRUCTURAL HEART DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     STRUCTURAL HEART DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2015–2020)
      • FIGURE 9     STRUCTURAL HEART DEVICE GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     STRUCTURAL HEART DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 12     ANNULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     OCCLUSION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 14     MECHANICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 15     TISSUE VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 16     TAVR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 17     TAVR DEVICES EUROPE MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 18     TAVR DEVICES U.S. MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 19     VALVULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 20     GLOBAL TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 21     U.S. TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 22     CHINA TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 23     GLOBAL TMVR AND TMVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 24     GLOBAL TPVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 25     CHINA TPVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
      • FIGURE 26     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 27     STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 28     ANNULOPLASTY GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 29     TRANSCATHETER MITRAL VALVE REPAIR DEVICES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 30     STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 31     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 32     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 33     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BY INDICATION (2020 V/S 2027) (%)
      • FIGURE 34     HEART VALVE DISEASES GLOBAL MARKET SHARE, BY INDICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 35     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 36     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
      • FIGURE 37     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 38     NORTH AMERICA STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 39     NORTH AMERICA STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 40     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
      • FIGURE 41     NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 42     U.S. STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 43     REST OF NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 44     EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 45     EUROPE STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 46     EUROPE STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 47     EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
      • FIGURE 48     EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 49     GERMANY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 50     ITALY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 51     FRANCE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 52     REST OF EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 53     APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 54     APAC STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 55     APAC STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 56     APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
      • FIGURE 57     APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 58     JAPAN STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 59     CHINA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 60     INDIA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 61     REST OF APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 62     ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 63     ROW STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 64     ROW STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 65     ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
      • FIGURE 66     ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 67     BRAZIL STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 68     TURKEY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 69     REST OF LATAM & MEA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
      • FIGURE 70     KEY GROWTH STRATEGIES, (2018-2020)
      • FIGURE 71     SWOT: ABBOTT LABORATORIES
      • FIGURE 72     SWOT: ATRICURE INC.
      • FIGURE 73     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 74     SWOT: CRYOLIFE INC.
      • FIGURE 75     SWOT: EDWARDS LIFESCIENCES CORPORATION
      • FIGURE 76     SWOT: LIFETECH SCIENTIFIC
      • FIGURE 77     SWOT: LIVANOVA PLC
      • FIGURE 78     SWOT: MEDTRONIC PLC.
      • FIGURE 79     SWOT: NUMED INC.
      • FIGURE 80     SWOT: VENUS MEDTECH

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Abbott Laboratories
      • 2     Affluent Medical
      • 3     Agile MV
      • 4     Anteris Technologies Ltd
      • 5     AtriCure, Inc.
      • 6     Balt Extrusion
      • 7     Becton, Dickinson and Company (Bard Peripheral Vascular Inc.)
      • 8     BioStable Science & Engineering, Inc.
      • 9     Bioventrix Inc.
      • 10     Boston Scientific Corporation
      • 11     Braile Biomedica
      • 12     Cardia Inc.
      • 13     Cardiac Dimensions, Inc.
      • 14     Cardiawave
      • 15     Cardiosolutions, Inc.
      • 16     CardioValve
      • 17     Colibri Heart Valve LLC
      • 18     Coroneo
      • 19     CroíValve
      • 20     Cryolife Inc.
      • 21     Edwards Lifesciences Corporation
      • 22     FOC Medical S.A
      • 23     Genesee BioMedical, Inc.
      • 24     Heart Leaflet Technologies (Part of Bracco Group)
      • 25     HighLife SAS
      • 26     Innovheart s.r.l
      • 27     Innovus
      • 28     JC Medical, Inc.
      • 29     JenaValve Technology, Inc.
      • 30     Labcor Laboratories LTDA
      • 31     Lepu Medical Technology (Beijing) Co., Ltd
      • 32     LifeNet Health Inc.
      • 33     Lifetech Scientific (Shenzhen) Co., Ltd.
      • 34     Livanova PLC
      • 35     Mardil Medical
      • 36     Medtentia International Ltd Oy
      • 37     Medtronic
      • 38     Meril Life Sciences Pvt. Ltd.
      • 39     Micro Interventional Devices, Inc.
      • 40     MicroPort Scientific Corporation
      • 41     MitrAssist Ltd.
      • 42     NaviGate Cardiac Structures, Inc.
      • 43     NeoChord, Inc.
      • 44     NeoVasc Inc.
      • 45     Numed Inc.
      • 46     Occlutech International AB
      • 47     OSYPKA AG
      • 48     Peijia Medical Limited
      • 49     pfm Medical Ag
      • 50     Sahajanand Medical Technologies Pvt Ltd (Vascular Innovations Co., Ltd.)
      • 51     Strait access technologies Pty ltd
      • 52     Thubrikar Aortic Valve, Inc.
      • 53     Toray Medical Co. Ltd. (Toray Industries)
      • 54     TTK Healthcare Limited (TTK Chitra Group)
      • 55     Valcare Medical
      • 56     Venus Medtech (Hangzhou) Inc.
      • 57     Vesalius Cardiovascular
      • 58     W. L. Gore & Associates, Inc.
      • 59     Xeltis AG
      • 60     Xuzhou Yatai Sci-tech Co. Ltd